The SARS-CoV-2 3-chymotrypsin-like protease (3CLpro or Mpro) is a key cysteine protease for viral replication and transcription, making it an attractive target for antiviral therapies to combat the COVID-19 disease. Here, we demonstrate that bismuth drug colloidal bismuth subcitrate (CBS) is a potent inhibitor for 3CLpro and . Rather than targeting the cysteine residue at the catalytic site, CBS binds to an allosteric site and results in dissociation of the 3CLpro dimer and proteolytic dysfunction. Our work provides direct evidence that CBS is an allosteric inhibitor of SARS-CoV-2 3CLpro.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565384PMC
http://dx.doi.org/10.1039/d1sc03526fDOI Listing

Publication Analysis

Top Keywords

colloidal bismuth
8
bismuth subcitrate
8
allosteric inhibition
4
inhibition sars-cov-2
4
sars-cov-2 3cl
4
3cl protease
4
protease colloidal
4
subcitrate sars-cov-2
4
sars-cov-2 3-chymotrypsin-like
4
3-chymotrypsin-like protease
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!